

Sativa Group PLC

11:00 21 Mar 2019

Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility

Sativa Investments PLC (LON:SATI) has completed its 1000th test of cannabinoid and terpenes at its on-site PhytoVista testing laboratory.

Cannabinoids are a class of around 113 compounds found in cannabis plants and include its medicinal component cannabidiol (CBD) and the psychoactive chemical tetrahydrocannabinol (THC).

READ: Sativa Investments brings in expert to aid its move into the CBD veterinary market

Terpenes are essential oils extracted from the cannabis plant that can enhance the effects of its various cannabinoids, with most of them also carrying anti-pain or anti-inflammatory benefits.

The cannabis investment firm said increased growth of the CBD industry in the UK had led to a rise in demand for testing and batch certifications, of which PhytoVista is a leading service provider.

The laboratory is designed to test and certify that products and samples conform to regulation and is believed to be the only CBD-focused facility in the UK. Sativa said the lab is aiming to test medicinal cannabis products once it has a handling licence granted by the Home Office.

The company added that it had recruited an analytical chemist and a microbiologist at the lab to help expand capacity while its chief scientific officer, Nick Clarkson, was developing new testing methods while the firm sought accreditation of ISO 17025, which regulates the competency of laboratories.

PhytoVista already operates with an ISO 17025 accreditation.

Jeremy Thomas, founder and chief executive of Sativa, said the 1000th test was "an early milestone" in the company's "holistic seed-to-consumer strategy", with PhytoVista "a key part of Sativa's internal strategic development as having an in-house, on-site testing facility is assisting the Company's Home Office Research Licence application".

"The laboratory is also attracting significant interest from the pharmaceutical and academic research areas which need an independent testing facility that mandates Good Laboratory Practice to verify and validate their own findings", he added.

The company's shares, which are traded on the NEX exchange, were at 5.9p in late-morning on Thursday.

--Adds share price--

Price: 5.65

Market Cap: 0

1 Year Share Price Graph



December 2018 June 2019 December 20

Share Information

Code: SATI

Listing: NEX

Sector: **Medical technology & services**

Website: sativainvestments.co.uk

Company Synopsis:

"Sativa Group PLC is the UK's first listed medicinal cannabis company. Sativa is capitalising on its first-mover advantage and is developing a substantial UK bridgehead in what the Company believes will be a significant market in the future."

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).